All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma

By

Supported by an independent educational grant from Jazz Pharmaceuticals

5d ago· 2 min readenInsight
educationhealth

Summary

This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features insights from Dr. Elena Elimova, a medical oncologist at Princess Margaret Cancer Center, who discloses her financial relationships with numerous pharmaceutical companies. The content is aimed at healthcare professionals seeking continuing education on targeted therapies for HER2-positive gastrointestinal cancers.

Source

Twitter / XPersonalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinomamdsc.pe

Key quotes

· 2 pulled
Elena Elimova, MD, has the following relevant financial relationships: Consultant or advisor for: AbbVie Inc.; Adaptimmune; Amgen, Inc.; Astellas Pharma, Inc.; BeiGene (Beijing) Co., Ltd.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Jazz Pharmaceuticals, Inc.; Natera; Novartis; Roche; Viracta Tx; Zymeworks
Research funding from: Amgen, Inc.; Arcus Biosciences; AstraZeneca; Bold Th
Snippet from the RSS feed
Stay current with evolving strategies for HER2-positive gastroesophageal adenocarcinoman (GEA). Improve your practice with continuing education activities, expert discussions, and other helpful tools.

You might also wanna read

OPTIMA Trial: Genomic Testing May Allow Some High-Risk Breast Cancer Patients to Skip Chemotherapy

The OPTIMA phase 3 trial, presented at the 2026 ASCO annual meeting, found that some women with high-risk, ER-positive, HER2-negative early

bcrf.org·4h ago

Combination therapy with RAS inhibitors shows promise for pancreatic cancer regression and resistance prevention

This research article presents a study on a targeted combination therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest c

pnas.org·14d ago

UC San Diego AI Model Predicts Cancer Treatment Response from Tumor Genetics

UC San Diego researchers have developed an AI tool called iAtlas that can predict how a tumor will respond to treatment based solely on its

today.ucsd.edu·28d ago

Personalized mRNA vaccine shows promise in preventing melanoma recurrence when combined with immunotherapy

An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined

share.google·22d ago

Ask HN: What is the latest on treatment of Metastatic Breast Cancer?

news.ycombinator.com·1y ago

Study reveals resistance mechanisms and potential treatment strategy for anaplastic thyroid cancer using type II RAF inhibitors

This study investigates resistance mechanisms to MAPK inhibition in anaplastic thyroid cancer (ATC), a highly lethal cancer. Using multi-reg

cell.com·4d ago

Comments

Sign in to join the conversation.

No comments yet. Be the first.